PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

sulfasalazine Side Effects

The reactions most often reported to the FDA for sulfasalazine (also sold as Azulfidine), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

76,270
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2003 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of sulfasalazine come from 76,270 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 76,270 reports to the FDA Adverse Event Reporting System (FAERS) for sulfasalazine (Azulfidine): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

76,270

Reports Mentioning Death

6,629

8.7% of reports — not proof the medicine caused the death

Hospitalizations

20,613

27.0% of reports

Top Indication

Rheumatoid Arthritis

Most Reported Adverse Reactions

RHEUMATOID ARTHRITIS
19,190
PAIN
15,658
ARTHRALGIA
13,161
FATIGUE
13,017
JOINT SWELLING
12,481
RASH
10,678
ABDOMINAL DISCOMFORT
9,801
CONTRAINDICATED PRODUCT ADMINISTERED
9,454
CONDITION AGGRAVATED
9,374
ALOPECIA
9,277
ARTHROPATHY
9,001
SYNOVITIS
8,965
TREATMENT FAILURE
8,687
SYSTEMIC LUPUS ERYTHEMATOSUS
8,588
SWELLING
8,508
NAUSEA
8,384
DRUG HYPERSENSITIVITY
8,282

Who Reports Side Effects

Gender Distribution

Female 52,098 (77%)
Male 15,843 (23%)
Unknown 77

Age Distribution

0-17 1,085 (2%)
18-44 12,906 (27%)
45-64 20,646 (44%)
65-74 8,320 (18%)
75+ 4,155 (9%)

Reporting Trend by Year

2003 2025

Reactions in Death Reports

Top reactions reported in 6,629 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
RHEUMATOID ARTHRITIS 2,082
SYSTEMIC LUPUS ERYTHEMATOSUS 2,074
TYPE 2 DIABETES MELLITUS 2,028
JOINT SWELLING 1,999
SYNOVITIS 1,970
RASH 1,961
GLOSSODYNIA 1,958
WOUND 1,945
PSORIATIC ARTHROPATHY 1,939
INFUSION RELATED REACTION 1,933
PAIN 1,910
GENERAL PHYSICAL HEALTH DETERIORATION 1,904
HAND DEFORMITY 1,874
HYPOAESTHESIA 1,874
FATIGUE 1,871
FIBROMYALGIA 1,869
SWELLING 1,847
HEPATIC ENZYME INCREASED 1,840
DUODENAL ULCER PERFORATION 1,834

Reactions in Hospitalization Reports

Top reactions in 20,613 reports where hospitalization was an outcome.

Reaction Reports
RHEUMATOID ARTHRITIS 5,015
PAIN 4,516
ARTHRALGIA 4,487
JOINT SWELLING 4,240
FATIGUE 4,179
RASH 3,909
CONDITION AGGRAVATED 3,681
SYNOVITIS 3,637
DRUG HYPERSENSITIVITY 3,524
ARTHROPATHY 3,515
NAUSEA 3,311
INFUSION RELATED REACTION 3,271
HYPERSENSITIVITY 3,192
PERIPHERAL SWELLING 3,191
ABDOMINAL DISCOMFORT 3,184
VOMITING 3,105
DIARRHOEA 3,103

Compare sulfasalazine vs abatacept →

What the FAERS Data Reveals About sulfasalazine Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 76,270 voluntary reports linked to sulfasalazine and its brand equivalents (Azulfidine), spanning 2003 through 2025. Of those, 6,629 (8.7%) listed death as an outcome and 20,613 (27.0%) involved hospitalization. The most common indication reported alongside adverse events was Rheumatoid Arthritis.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 77% were female and 23% male; age distribution skews toward 45-64, with 20,646 reports in that bracket. The single most reported reaction is rheumatoid arthritis with 19,190 submissions, followed by pain and arthralgia.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.